Scientists have unveiled the first body-wide single-cell genome map, offering a groundbreaking insight into the intricate world of epigenetics. This achievement, published in Science, is a significant step forward in our understanding of how cells use the same DNA code to perform diverse functions. The study, led by researchers at the Salk Institute and Arc Institute, along with collaborators, has created a comprehensive atlas spanning 86,689 cells from 16 human tissues, revealing 35 major cell types and 206 subtypes. This resource is freely available online, providing a wealth of data for scientists and artificial intelligence tools to explore.
One of the key findings is the discrepancy between DNA methylation and 3D genome structure in different cell types. For instance, in skeletal muscle, cells that appear mature and differentiated based on their 3D genome folding still carry the methylation signature of muscle stem cells. This suggests that these cells are in the process of differentiation, with the 3D architecture updating first and methylation following suit. Such insights challenge our understanding of cell types in adult tissues and how they transition in disease states.
The atlas also revises our understanding of 'non-CG methylation', previously thought to be confined to brain cells and stem cells. It is now clear that this form of methylation carries cell-identity information across many human tissues, including muscle, pancreas, and immune cell types, at lower but biologically meaningful levels. This finding has significant implications for our understanding of disease-associated genetic variants, many of which are found in non-coding regions of the genome.
The study's interactive web browser is a valuable resource for researchers, allowing them to visualize DNA methylation and 3D chromatin contacts across every tissue, cell type, and subtype in the study. This tool is particularly useful for artificial intelligence models that predict the functional impact of genetic variants. For example, in a companion paper, researchers used the atlas' cross-tissue methylation data to show that the brain's resident immune cells, called microglia, are replaced by cells resembling blood monocytes between roughly ages 50 and 75, challenging the long-held view that microglia persist from embryonic development throughout life.
The NIH 4D Nucleome consortium, of which this study is a part, aims to extend this kind of mapping into the fourth dimension: time. A 4D understanding of the genome—how its structure and chemistry change as cells develop, age, and respond to disease—remains a major goal. The cross-tissue atlas provides a reference scaffolding that future time-course studies will build on, offering a promising avenue for further research and discovery.
In my opinion, this study is a significant milestone in epigenetics research, offering a wealth of data and insights that will shape our understanding of cell biology and disease. The ability to map the genome at the single-cell level and across different tissues and time points is a powerful tool that will undoubtedly drive future discoveries in the field.
